ArticleJAC-antimicrobial resistance2025
Antimicrobial resistance trends of methicillin-resistant
Article in JAC-antimicrobial resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Mapping the antimicrobial susceptibility of methicillin-resistantMicrobiology spectrum · 2026Article
- Genomic insights and emerging therapeutics in community-associated MRSA.Annals of medicine and surgery (2012) · 2026Article
- Unmasking Methicillin-resistantFrontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The purpose of this study was to analyse nationwide trends in antimicrobial susceptibility and molecular epidemiology of all MRSA strains in Norway over a 10-year period. Materials and methods: All cases of MRSA in Norway from 2008 to 2017 were included, limited to the first case per year per individual ( Results: Despite an increase in MRSA cases, antimicrobial resistance rates remained stable throughout the study period. The most common susceptibility profile of the MRSA strains was resistance to cefoxitin alone (41.4%), while co-resistance (58.6%) was observed most commonly for erythromycin (31.0%), tetracycline (25.3%) and ciprofloxacin/norfloxacin (21.6%). Notably, associations were identified between specific resistance patterns and clinical variables, including higher resistance rates among healthcare-associated MRSA, particularly in older adults and nursing home residents. Geographic associations were also observed, linking specific resistance profiles to strains acquired in North America, Africa and Asia. Conclusions: The findings highlight a complex landscape of MRSA resistance in a low-prevalence country, characterized by a diverse genotypic population and stable longitudinal trends in resistance rates. However, the prevalence of co-resistance to one or more antibiotics among Norwegian MRSA strains was high and increasing. This study thus underscores the importance of continuous surveillance and adherence to antimicrobial guidelines.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.